Lilly Delivers Solid Third-Quarter 2018 Results, Revises EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Eli Lilly (LLY) PT Lowered to $124 at BMO Capital
November 7, 2018 12:40 PM ESTBMO Capital analyst Alex Arfaei lowered the price target on Eli Lilly (NYSE: LLY) to $124.00 (from $130.00) while maintaining an Outperform rating.
The analyst comments, "Lilly had a mixed, incrementally negative 3Q18, but our thesis is unchanged. Although price pressure in the... More
Eli Lilly & Co. (LLY) Tops Q3 EPS by 4c, Raises FY EPS Guidance
November 6, 2018 6:26 AM EST(Updated - November 6, 2018 6:28 AM EST)
Eli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $1.39, $0.04 better than the analyst estimate of $1.35. Revenue for the quarter came in at $6.06 billion versus the consensus estimate of $6.05 billion.
GUIDANCE:
Eli Lilly & Co.... More
